Science and Enterprise

Month: August 2010

  • Texas City, University Get Grant for Sci/Tech Incubator

    A partnership between Texas State University-San Marcos and the city of San Marcos has landed a $1.85 million award from the U.S. Economic Development Administration to build a new Science, Technology, and Advanced Research (STAR) building. The university says the new building will be used as a location for start-up and early-stage businesses, and provide…

  • Study to Determine Genetic Risks of Gum Disease

    The University of Michigan School of Dentistry in Ann Arbor and Interleukin Genetics Inc. in Waltham, Massachusetts have agreed to conduct a large-scale clinical study using genetic testing to assess the risk for gum disease, specifically factors that predict periodontal disease progression to tooth loss. This study will determine if dental patients can be categorized…

  • Outcome Sciences to Study Effectiveness of Glaucoma Treatments

    The U.S. Agency for Healthcare Research and Quality has selected Outcome Sciences Inc. in Cambridge, Massachusetts, to conduct a study to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States, which aims to provide new scientific information about…

  • FDA Committee Advances Anti-Epileptic Drug

    GlaxoSmithKline in Research Triangle Park, North Carolina and Valeant Pharmaceuticals International in Aliso Viejo, California announced that a U.S. Food and Drug Administration (FDA) advisory committee voted that clinical studies offered substantial evidence of the effectiveness of the companies’ drug ezogabine as an added treatment for adults with partial-onset seizures. The FDA’s Peripheral and Central…

  • Fluor Corporation to Help Cobalt Technologies Produce Biofuels

    Cobalt Technologies, a developer of the renewable fuel biobutanol, in Mountain View, California, has signed an agreement with Fluor Corporation, a global engineering and project management company. Fluor will provide engineering, procurement, construction, and maintenance services to help Cobalt gear up for commercializing its biobutanol production technology, as well as for Cobalt’s demonstration and commercial-scale…

  • Patent Awarded for Low Testosterone Treatment

    Repros Therapeutics Inc. in the Woodlands, Texas announced the U.S. Patent and Trademark office has issued a patent for Androxal, the company’s lead treatment for low testosterone in men. This patent claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism, when the sex glands produce little or no hormones.…

  • Alectos Therapeutics, Merck Collaborate on Alzheimer’s Drug

    Alectos Therapeutics Inc. in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company Merck & Co. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer’s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and…

  • Sanofi-aventis, Scripps to Partner on Personalized Medicines

    Sanofi-aventis (U.S.) in Bridgewater, New Jersey and Scripps Genomic Medicine in San Diego, California announced today an alliance to advance research initiatives in individualized medicine. Sanofi-aventis is a French pharmaceutical company, but with a U.S. subsidiary. Scripps Genomic Medicine is a division of Scripps Health, a private not-for-profit community health system in San Diego. In…

  • Nanomaterial Can Turn Ordinary Window Glass into Solar Power

    EnSol AS, a company in Bergen, Norway, working with the University of Leicester (U.K.) Department of Physics and Astronomy has developed and patented a thin film solar technology that can generate electric power when applied to common glass windows. The material developed by EnSol is composed of metal nanoparticles embedded in a transparent composite matrix.…

  • New iPhone App Tracks Side Effects in Clinical Trials

    The Center for Biomedical Informatics at The Children’s Hospital of Philadelphia converted all the reference information in the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) into a software application, or “app”,  for the Apple iPhone. With this iPhone app, physicians can replace the 200-page CTCAE manual, with a four-ounce iPhone or iPod…